{
    "2019-10-29": [
        [
            {
                "time": "",
                "original_text": "【民生医药|跟踪点评】泰格医药：与日本CRO合作深化，关注国际化拓展进度",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "日本CRO",
                        "合作深化",
                        "国际化拓展"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "泰格医药现1笔大宗交易 共成交259.05万元",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "大宗交易",
                        "成交金额"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药：拟收购日本EPS部分股权 拓展亚太区业务",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "收购",
                        "日本EPS",
                        "亚太区业务"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【医药】300347*泰格医药:Q3单季扣非净利翻倍，业绩持续高增长超预期*买入",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "Q3",
                        "扣非净利翻倍",
                        "业绩高增长",
                        "买入"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【川财研究所*常规报告】泰格医药（300347）：Q3收入端增速略有放缓，利润持续兑现 盈利能力下降",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "Q3",
                        "收入端增速放缓",
                        "利润持续兑现",
                        "盈利能力下降"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "格力“招亲”选定高瓴 就等董小姐说“我愿意”",
                "features": {
                    "keywords": [
                        "格力",
                        "招亲",
                        "高瓴",
                        "董明珠"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "家电"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "格力混改尘埃落定! 高瓴资本张磊入驻董明珠仍居C位!",
                "features": {
                    "keywords": [
                        "格力",
                        "混改",
                        "高瓴资本",
                        "张磊",
                        "董明珠"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "家电"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}